Other substances

Azoximer bromide

An immunomodulatory synthetic polymer.

Phase of research

Potential treatment - clinical evidence

How it helps

Other treatment

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
2
 Clinical trials

General information

Azoximer bromide is a high-molecular weight synthetic polymer. It is used as an immunomodulatory drug (Efimov et al., 2021).

Azoximer bromide on DrugBank
Azoximer bromide on Wikipedia

Marketed as

POLYOXIDONIUM

 

Structure image - Azoximer bromide

Supporting references

Link Tested on Impact factor Notes Publication date
The effect of azoximer bromide (Polyoxidonium®) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study
Severe severity Mild severity Cohort study 		Patients 3.56

The treatment was safe. Generally, gradual clinical improvement was observed, more pronounced in severe COVID-19 patients. Sample size: 10 mild + 22 severe. Dosage: 12 mg IV daily on days 1–3; 12 mg IM every other day during days 4–16. Primary outcome: Clinical status on an ordinal scale on day 15.



 Mar/25/2021

AI-suggested references

Link Publication date
Open-label use of an aliphatic polyamine immunomodulator in patients hospitalized with COVID-19
Mar/03/2022
The effect of azoximer bromide (Polyoxidonium ) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.
Mar/25/2021

Clinical trials

ID Title Status Phase Start date Completion date
NCT04381377 Efficacy and Safety of Polyoxidonium® in Hospitalized Patients With Coronavirus Disease COVID-19 Active, not recruiting Phase 2|Phase 3 Apr/29/2020 Apr/01/2021
  • Alternative id - PО-COV-III-20
  • Interventions - Drug: azoximer bromide|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Regional state budgetary institution of public health "City hospital No. 5 of Barnaul", Barnaul, Russian Federation|Central Research Institute of Epidemiology of Rospotrebnadzor, Moscow, Russian Federation|The state healthcare institution of the city of Moscow "City Clinical Hospital No. 15 named after OM Filatov" in "Moscow City Department of Health", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "Infectious Clinical Hospital No. 1 of the Moscow Department of Healthcare", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 24 of the Moscow Department of Healthcare", Moscow, Russian Federation|State budgetary institution "Research Institute of Emergency Care named after N.V. Sklifosovsky in Department of Health of the city of Moscow", Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution "City Clinical Hospital No. 40 of the Moscow Department of Healthcare", Moscow, Russian Federation|State budgetary institution of health care of the Nizhny Novgorod region "Infectious clinical hospital No. 2 of Nizhny Novgorod", Nizhny Novgorod, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "Orenburg State Medical University" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|Federal State Budgetary Educational Institution of Higher Education "First St. Petersburg State Medical University named after Academician I.P. Pavlov, Saint Petersburg, Russian Federation|State budgetary health institution of the Vladimir region "Regional Clinical Hospital", Vladimir, Russian Federation|Yaroslavl State Medical University of Ministry of Health of the Russian Federation, Yaroslavl, Russian Federation|Clinics of Infectious Diseases, University Hospital in Nitra, Nitra, Slovakia|Clinics of Infectious Diseases, University Hospital in Trnava, Trnava, Slovakia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 394
  • Age - 18 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Clinical status of the patient (according to 7-point ordinal scale)|NEWS|Oxygenation|Mechanical Ventilation|Mortality
NCT04542226 Observational Open Study of Polyoxidonium in Hospitalized Patients With COVID-19 Completed Mar/31/2020 Oct/30/2020
  • Alternative id - Covid_v_1.0
  • Interventions - Drug: Polyoxidonium
  • Study type - Observational
  • Study results - Has Results
  • Locations - Healthcare Institution "Grodno Regional Infectious Clinical Hospital", Grodno, Belarus|State-Funded Healthcare Institution "Emergency Hospital" of Ministry of Health of Chuvash Republic, Cheboksary, Chuvashia, Russian Federation|State-Funded Healthcare Institution "Infectious Disease Hospital No.3" of Ministry of Health of Krasnodar Krai, Novorossiysk, Krasnodar Krai, Russian Federation|State-Funded Institution of Mari El Republic "Yoshkar-Ola City Hospital", Yoshkar-Ola, Mari El Republic, Russian Federation|State-Funded Healthcare Institution of Voronezh Region "Novaya Usman District Hospital", Novaya Usman, Voronezh Region, Russian Federation
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 81
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Status of the Patient (According to 7-point Ordinal Scale)|Time to Improvement in Clinical Status of the Patient (According to Ordinal Scale) by 1 Point for Each OS Score|Clinical Status of the Patient (According to National Early Warning Score (NEWS Scale))|Number of Patients Requiring Supplementary Oxygen|Hospitalisation Duration|Mortality|The Number of Participants With Serious Adverse Events|The Number of Participants With Adverse Events|Number of Participants With Discontinuation of Drug Administration
Export (.csv)